ECSP19078393A - Compuestos inhibidores de ask1 y usos de los mismos - Google Patents

Compuestos inhibidores de ask1 y usos de los mismos

Info

Publication number
ECSP19078393A
ECSP19078393A ECSENADI201978393A ECDI201978393A ECSP19078393A EC SP19078393 A ECSP19078393 A EC SP19078393A EC SENADI201978393 A ECSENADI201978393 A EC SENADI201978393A EC DI201978393 A ECDI201978393 A EC DI201978393A EC SP19078393 A ECSP19078393 A EC SP19078393A
Authority
EC
Ecuador
Prior art keywords
compounds
same
inhibiting compounds
ask1
methods
Prior art date
Application number
ECSENADI201978393A
Other languages
English (en)
Spanish (es)
Inventor
Samuel David Brown
Original Assignee
Seal Rock Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seal Rock Therapeutics Inc filed Critical Seal Rock Therapeutics Inc
Publication of ECSP19078393A publication Critical patent/ECSP19078393A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
ECSENADI201978393A 2017-04-05 2019-10-31 Compuestos inhibidores de ask1 y usos de los mismos ECSP19078393A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762482085P 2017-04-05 2017-04-05

Publications (1)

Publication Number Publication Date
ECSP19078393A true ECSP19078393A (es) 2019-12-27

Family

ID=63712299

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201978393A ECSP19078393A (es) 2017-04-05 2019-10-31 Compuestos inhibidores de ask1 y usos de los mismos

Country Status (34)

Country Link
US (3) US20210087167A1 (enExample)
EP (1) EP3606519B1 (enExample)
JP (1) JP7196093B2 (enExample)
KR (1) KR102665145B1 (enExample)
CN (1) CN110730661B (enExample)
AR (1) AR111407A1 (enExample)
AU (1) AU2018250217B2 (enExample)
CA (1) CA3059107A1 (enExample)
CL (1) CL2019002810A1 (enExample)
CO (1) CO2019011708A2 (enExample)
CR (1) CR20190503A (enExample)
CU (1) CU20190080A7 (enExample)
DK (1) DK3606519T3 (enExample)
DO (1) DOP2019000255A (enExample)
EA (1) EA201992299A1 (enExample)
EC (1) ECSP19078393A (enExample)
ES (1) ES2992084T3 (enExample)
FI (1) FI3606519T3 (enExample)
HU (1) HUE068103T2 (enExample)
IL (1) IL269711B (enExample)
JO (1) JOP20190221A1 (enExample)
MA (1) MA49047A (enExample)
MX (1) MX394098B (enExample)
NI (1) NI201900102A (enExample)
NZ (1) NZ758345A (enExample)
PE (1) PE20200009A1 (enExample)
PH (1) PH12019502288A1 (enExample)
PL (1) PL3606519T3 (enExample)
PT (1) PT3606519T (enExample)
RU (1) RU2019134679A (enExample)
SG (1) SG11201909155VA (enExample)
SI (1) SI3606519T1 (enExample)
TW (1) TWI779022B (enExample)
WO (1) WO2018187506A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6754505B2 (ja) * 2017-01-22 2020-09-09 福建広生堂薬業股▲ふん▼有限公司 Ask1阻害剤、その調製方法および使用
US10683279B2 (en) 2017-05-12 2020-06-16 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
EP3735404B1 (en) 2018-01-02 2023-11-29 Seal Rock Therapeutics, Inc. Ask1 inhibitor compounds and uses thereof
CN110407806B (zh) * 2018-04-28 2021-08-17 深圳微芯生物科技股份有限公司 甲酰胺类化合物、其制备方法及其应用
IL278368B2 (en) 2018-05-02 2024-06-01 Enanta Pharm Inc Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020006429A1 (en) * 2018-06-28 2020-01-02 Hepatikos Therapeutics, Llc Ask1 isoindolin-1-one inhibitors and methods of use thereof
US10968199B2 (en) 2018-08-22 2021-04-06 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11345699B2 (en) 2018-11-19 2022-05-31 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020198214A1 (en) * 2019-03-25 2020-10-01 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN112409332B (zh) * 2019-08-23 2023-12-08 广东东阳光药业股份有限公司 三氮唑衍生物及其在药物中的应用
PE20221283A1 (es) 2019-12-27 2022-09-05 Lupin Ltd Compuestos triciclicos sustituidos
CN115698004A (zh) 2020-05-01 2023-02-03 辉瑞公司 作为hpk1抑制剂的氮杂内酰胺化合物
WO2021224818A1 (en) * 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
US20230271940A1 (en) * 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2024020458A1 (en) * 2022-07-20 2024-01-25 Seal Rock Therapeutics, Inc. Method of treating organ diseases or disorders with ask1 inhibitors
WO2025233319A1 (en) 2024-05-06 2025-11-13 Genfit (1,2,4-triazol-3-yl)-2-pyridyl-1-isoindolinone for use in the treatment of sepsis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
TWI625121B (zh) * 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
HRP20140114T1 (hr) * 2010-02-03 2014-03-14 Takeda Pharmaceutical Company Limited Inhibitori kinaze 1 koji reguliraju signal apoptoze
WO2012079022A1 (en) * 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
PL2651417T3 (pl) 2010-12-16 2017-08-31 Calchan Limited Pochodne pirolopirymidyny hamujące ASK1
NZ729678A (en) * 2014-09-24 2018-07-27 Gilead Sciences Inc Methods of treating non-alcoholic steatohepatitis using ask1 inhibitor in combination with a fxr agonist
US10669242B2 (en) 2016-06-10 2020-06-02 Venenum Biodesign, LLC Clostridium difficile toxin inhibitors
JP6754505B2 (ja) 2017-01-22 2020-09-09 福建広生堂薬業股▲ふん▼有限公司 Ask1阻害剤、その調製方法および使用
CN109071538B (zh) 2017-01-22 2020-03-17 福建广生堂药业股份有限公司 作为ask1抑制剂的吡啶衍生物及其制备方法和应用
ES2926449T3 (es) 2017-02-07 2022-10-26 Biogen Ma Inc Agentes inhibidores de ASK1
CN109071498B (zh) 2017-02-16 2021-03-30 四川科伦博泰生物医药股份有限公司 激酶抑制剂及其制备方法和用途
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
WO2018157277A1 (en) 2017-02-28 2018-09-07 Eli Lilly And Company Isoquinolin and naphthydrin compounds
WO2018157856A1 (zh) 2017-03-03 2018-09-07 江苏豪森药业集团有限公司 酰胺类衍生物抑制剂及其制备方法和应用
WO2018183122A1 (en) 2017-03-27 2018-10-04 Sidecar Therapeutics, Inc. Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds
US20200308165A1 (en) 2017-09-13 2020-10-01 D.E. Shaw Research, Llc Compounds as Ras Inhibitors and Use Thereof
WO2020006429A1 (en) 2018-06-28 2020-01-02 Hepatikos Therapeutics, Llc Ask1 isoindolin-1-one inhibitors and methods of use thereof

Also Published As

Publication number Publication date
WO2018187506A1 (en) 2018-10-11
NI201900102A (es) 2020-05-15
IL269711B (en) 2021-12-01
DOP2019000255A (es) 2019-12-15
CO2019011708A2 (es) 2020-01-17
AU2018250217A1 (en) 2019-11-07
EP3606519A1 (en) 2020-02-12
US10150755B2 (en) 2018-12-11
MX394098B (es) 2025-03-24
CU20190080A7 (es) 2020-10-20
US20250304552A1 (en) 2025-10-02
TWI779022B (zh) 2022-10-01
RU2019134679A (ru) 2021-05-05
US20210087167A1 (en) 2021-03-25
TW201838983A (zh) 2018-11-01
PH12019502288A1 (en) 2020-07-13
CR20190503A (es) 2020-02-28
SG11201909155VA (en) 2019-10-30
KR102665145B1 (ko) 2024-05-09
MA49047A (fr) 2020-02-12
BR112019021021A2 (pt) 2020-05-05
IL269711A (en) 2019-11-28
AR111407A1 (es) 2019-07-10
FI3606519T3 (fi) 2024-08-09
PL3606519T3 (pl) 2024-10-28
PT3606519T (pt) 2024-08-06
SI3606519T1 (sl) 2024-10-30
JOP20190221A1 (ar) 2019-09-23
MX2019012013A (es) 2019-12-18
CL2019002810A1 (es) 2020-03-27
AU2018250217B2 (en) 2022-05-19
CN110730661A (zh) 2020-01-24
US20180291002A1 (en) 2018-10-11
PE20200009A1 (es) 2020-01-06
CA3059107A1 (en) 2018-10-11
JP7196093B2 (ja) 2022-12-26
CN110730661B (zh) 2023-06-13
HUE068103T2 (hu) 2024-12-28
JP2020515589A (ja) 2020-05-28
KR20190141166A (ko) 2019-12-23
EP3606519A4 (en) 2020-12-02
EA201992299A1 (ru) 2020-03-26
ES2992084T3 (es) 2024-12-09
NZ758345A (en) 2022-02-25
DK3606519T3 (da) 2024-08-12
EP3606519B1 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
ECSP19078393A (es) Compuestos inhibidores de ask1 y usos de los mismos
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CL2020000747A1 (es) Formulaciones de niraparib.
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2019009722A2 (es) Dendrímeros terapéuticos
CL2018002784A1 (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue.
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY36124A (es) Derivados de carboxamida
UY36123A (es) Derivados de carboxamida
UY37872A (es) Derivados de difenilo y usos de los mismos
CO2021008962A2 (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos
CU20160170A7 (es) Derivados de carboxamida